Cocrystal Pharma (COCP) Non-Current Assets (2010 - 2026)
Cocrystal Pharma (COCP) posted Non-Current Assets of $1.5 million for Q1 2026, down 5.77% sequentially from $1.6 million in Q4 2025, and down 18.88% YoY from $1.8 million in Q1 2025.
Cocrystal Pharma (COCP) Non-Current Assets (2010 - 2026) Analysis & Trends
Cocrystal Pharma has reported Non-Current Assets for 16 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 18.88% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 14.87% YoY) and the FY2025 annual result came in at $1.6 million, down 15.88% from the prior year.
- Non-Current Assets retreated to $1.5 million in Q1 2026 per COCP's latest filing, from $1.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $20.0 million in Q1 2022 and troughed at $409000.0 in Q3 2023.
- A 5-year average of $2.5 million and a median of $1.7 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets plunged 96.97% in 2023, then jumped 383.37% in 2024.
- Over 5 years, Non-Current Assets stood at $662000.0 in 2022, then soared by 227.49% to $2.2 million in 2023, then fell by 13.47% to $1.9 million in 2024, then fell by 15.88% to $1.6 million in 2025, then retreated by 5.77% to $1.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.5 million, $1.6 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | 18.06 Bn |
| 10 | Cocrystal Pharma | 16.41 Mn | 14.09 Mn | - | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.41 Mn |
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.66 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 1.88 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 2.05 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 409,000.00 |
| Jun 30, 2023 | 518,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Dec 31, 2022 | 662,000.00 |
| Sep 30, 2022 | 751,000.00 |
| Jun 30, 2022 | 787,000.00 |
| Mar 31, 2022 | 19.97 Mn |
| Dec 31, 2021 | 20.07 Mn |
| Sep 30, 2021 | 20.16 Mn |